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Abstract
Background: There is increasing evidence that the presence of an ongoing systemic inflammatory response is
associated with poor prognosis in patients with advanced cancers. We evaluated the relationships between clinical
status, laboratory factors and progression free survival (PFS), and overall survival (OS) in patients with recurrent or
metastatic gastric cancer receiving first-line palliative chemotherapy.
Methods: We reviewed 402 patients with advanced gastric adenocarcinoma who received first-line palliative
chemotherapy from June 2004 and December 2009. Various chemotherapy regimens were used. Eastern
Cooperative Oncology Group performance status (ECOG PS), C-reactive protein (CRP), albumin, Glasgow prognostic
score (GPS), and clinical factors were recorded immediately prior to first-line chemotherapy. Patients with both an
elevated CRP (>1.0 mg/dL) and hypoalbuminemia (<3.5 mg/dL) were assigned a GPS of 2. Patients in whom only
one of these biochemical abnormalities was present were assigned a GPS of 1, and patients with a normal CRP
and albumin were assigned a score of 0. To evaluate the factors that affected PFS and OS, univariate and
multivariate analyses were performed.
Results: According to multivariate analysis, the factors independently associated with PFS were ECOG PS (HR 1.37,
95% CI 1.02-1.84, P = 0.035), bone metastasis (HR 1.74, 95% CI 1.14-2.65, P = 0.009), and CRP elevation (HR 1.64, 95%
CI 1.28-2.09, P = 0.001). The factors independently associated with OS were ECOG PS (HR 1.33, 95% CI 1.01-1.76, P =
0.037), bone metastasis (HR 1.61, 95% CI 1.08-2.39, P = 0.017), and GPS ≥ 1 (HR 1.76, 95% CI 1.41-2.19, P = 0.001).
Conclusions: The results of this study showed that the presence of a systemic inflammatory response as
evidenced by the CRP, GPS was significantly associated with shorter PFS and OS in patients with recurrent or
metastatic gastric cancer receiving first-line palliative chemotherapy. Bone metastasis and GPS were very useful
indicator for survival in patients with recurrent or metastatic gastric cancer receiving palliative chemotherapy.
Background
Recurred or metastatic gastric cancer has a very poor
prognosis, but chemotherapy can improve survival and
possibly provide significant palliation of symptoms.
Despite the recently reported benefits of chemotherapy,
the 5-year survival rate for recurred or metastatic gastric
cancer remains at ~ 5-20% [1-3]. Despite an often short
and poor overall survival, there is marked heterogeneity
in the duration of survival among patients. Therefore,
there have been continuing efforts to investigate the
prognostic factors related to survival [4,5].
C-reactive protein (CRP) is an acute phase protein
which is synthesized by hepatocytes and;its levels in the
serum increase during inflammatory diseases [6]. Cancer
growth and resultant invasion induce local tissue
damage, disturb local homeostasis, and cause systemic
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by which systemic inflammation arises in cancer patients
remains to be clarified, it is generally accepted that can-
cer associated inflammation is modulated by cancer
cells, host stromal cells, and their interactions [7].
There is increasing evidence that the presence of a
systemic inflammatory response, as evidenced by ele-
vated concentrations of CRP, is a prognostic factor in
patients with advanced cancer [8-10]. High CRP levels
are common in patients with advanced disease, because
advanced cancer is often associated with an inflamma-
tory response [7].
The Glasgow prognostic score (GPS) was introduced
as a useful predictor for survival in patients with cancer
by Forrest in 2003, and consists of the combination of 2
values, CRP and albumin [4,11]. It has been reported
that GPS was associated with prognosis in various types
of cancer including non small cell lung cancer, gastric
cancer, colorectal cancer, pancreatic cancer, and breast
cancer. Nearly all studies evaluated the prognostic value
of preoperative CRP in resettable tumors [12]. Clinical
factors such as liver metastasis, carcinomatosis peritonei,
and bone metastasis are easily identifiable and imply
that a patient has an advanced cancer. In this study, we
evaluated the relationships between carcinomatosis peri-
tonei, liver metastasis, bone metastasis, ECOG PS, albu-
min, CRP, GPS, and progression free survival (PFS), and
overall survival (OS) in patients with recurrent or meta-
static gastric cancer receiving first-line palliative
chemotherapy.
Methods
Patients
We evaluated patients with advanced gastric cancer who
had received palliative chemotherapy between June 2004
and December 2009 at Chonnam National University
Hwasun Hospital (Gwangju, Korea). Patients were
staged using a combination of endoscopy, computed
tomography (CT) scan of the chest and abdomen, and
additionally, positron emission tomography or bone
scan when clinically indicated.
The criteria for case inclusion were as follows: (1) his-
tologically confirmed gastric adenocarcinoma, (2) no
prior chemotherapy or radiotherapy except for adjuvant
treatment, (3) presence of metastatic disease, and (4)
availability of clinical data at the initiation of therapy
and follow-up. Of the 532 patients screened, 402 ful-
filled the inclusion criteria and were enrolled in this ret-
rospective analysis.
ECOG PS was evaluated according to the Eastern
Cooperative Oncology Group criteria. The clinical
tumor response was assessed radiologically by CT scan-
ning after every 2 or 3 courses of chemotherapy accord-
ing to the Response Evaluation Criteria in Solid Tumors
(RECIST version 1.0) and clinically based on control of
symptoms
Chemotherapy regimens had included a variety of
agents such as taxane, irinotecan, cisplatin, oxaliplatin,
5-FU, S-1, and capecitabine. Oral fluoropyrimidines
such as S-1 and capecitabine are replacing infusional 5-
FU, and doublet chemotherapy regimens were most
commonly used.
This study was approved by the institutional review
board of Chonnam National University Medical School
Research Institution (2011-109).
Measurement of serum CRP
Routine laboratory measurements of CRP and albumin
were carried out one day before the first cycle of che-
motherapy. The limit of detection of the CRP assay was
< 0.03 mg/dL, with the upper limit of normal values
being < 1.0 mg/dL. Serum CRP was measured by latex
t u r b i d i m e t r i ci m m u n o a s s a yu s i n gaH I T A C H I7 6 0 0
(Hitachi, Tokyo, Japan). The coefficients of variation for
these methods, over the range of measurements, were <
5%, as established by routine quality control.
The GPS was derived as previously described [4,11].
Patients with both an elevated CRP (> 1.0 mg/dL) and
hypoalbuminemia (< 3.5 mg/dL) were assigned a score
of 2. Patients in whom only one of these biochemical
abnormalities was present were assigned of 1. Patients
in whom neither of these abnormalities was present
were assigned a score of 0.
Statistics
The SPSS software package, version 17.0 (SPSS Inc, Chi-
cago, IL, USA) was used for statistical analysis. The
Kaplan-Meier analysis was applied to assess factors
affecting overall survival (OS) and progression free sur-
vival (PFS): (1) OS was defined as the time from the
first date of the first-line chemotherapy or to death
from any cause or the last follow-up visit (2) PFS was
defined as the time from the first date of the first-line
chemotherapy to disease progression. Factors included
in the univariate analysis using Kaplan-Meier methods
were age, gender, liver metastasis, peritoneal metastasis,
bone metastasis, albumin, CRP, ECOG PS, and GPS.
Among the factors, those with P < 0.2 were selected and
included in the multivariate regression analysis using
the Cox proportional hazards regression model, which
was performed to achieve an adjusted hazard ratio (HR)
to determine prognostic factors for OS and PFS. P <
0.05 was considered significant for all analyses.
Results
This study included a total of 402 patients who received
first-line chemotherapy in the Department of Oncology
at Chonnam National University Hwasun Hospital
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patient data from the cancer registry. All data were pro-
spectively recorded and only the survival data was
updated at the time of analyses. The median follow-up
time was 11.4 months and ranged from 1.1 months to
58.5 months. The baseline clinical characteristics of the
patients at the start of first-line chemotherapy are
shown in Table 1 and Table 2. The median age of the
patients was 59 years, with a range of 19-80 years. A
total of 203 patients (72.9%) were male, and 73 patients
(48.2%) had an ECOG PS of 2-3. A total of 125 patients
(31.1%) had liver metastases, and 159 patients (39.6%),
and 28 patients (7.0%) had peritoneal metastases and
bone metastases, respectively. A total of 140 patients
(34.9%) had an elevated CRP concentration (> 1 mg/dL),
and 77 patients (19.2%) had hypoalbuminemia (< 3.5
mg/dL).
The most commonly used first-line chemotherapy regi-
mens were taxanes and cisplatin (n = 191, 47.5%). The
specific chemotherapy regimens are shown in Table 3. A
complete response to first-line chemotherapy was achieved
in 25 patients (6.2%), and a partial response was achieved
in 120 patients (29.9%), giving an overall response rate of
36.1% and a disease control rate of 70.9%. The results of
chemotherapy are shown in Table 4. The median progres-
sion free survival was 4.4 months (95% CI 4.018-4.782),
and the median overall survival was 11.8 months (95% CI
10.727-12.873).
The univariate analysis demonstrated that 5 clinical
factors were significantly associated with a shorter PFS;
these factors included bone metastases, albumin < 3.5
Table 1 Univariate analysis of clinical factors and GPS for
progression free survival (n = 402)
Patients (%) mPFS months (95% CI) P-value
Age
<60 203 (50.5) 4.3 (3.8-4.7) 0.840
≥ 60 199 (49.5) 4.5 (3.9-5.1)
Gender
Male 293 (72.9) 4.5 (3.9-5.0) 0.381
Female 109 (27.1) 4.3 (3.6-4.9)
Liver Mets
Yes 125 (31.1) 4.1 (3.6-4.5) 0.243
No 277 (68.9) 4.6 (3.9-5.2)
Peritoneal Mets
Yes 159 (39.6) 4.3 (3.8-4.8) 0.128
No 243 (60.4) 4.6 (3.9-5.2)
Bone Mets
Yes 28 (7.0) 3.9 (2.4-5.3) 0.032
No 374 (93.0) 4.5 (4.0-5.0)
Albumin
<3.5 77 (19.2) 3.4 (2.2-4.5) 0.013
≥ 3.5 325 (80.8) 4.6 (4.1-5.2)
CRP
≤ 1 262 (65.1) 5.3 (4.5-6.0) 0.001
>1 140 (34.9) 3.4 (2.7-4.1)
ECOG PS
0-1 329 (81.8) 4.6 (4.0-5.1) 0.002
≥ 2 73 (48.2) 3.0 (2.0-3.9)
GPS
0 238 (59.2) 5.5 (4.8-6.2) 0.001
1 111 (27.6) 3.4 (2.7-4.1)
2 53 (13.2) 3.3 (2.0-4.7)
mPFS: median progression free survival, Mets: Metastasis, CRP: C-reactive
protein, ECOG PS: Eastern Cooperative Oncology Group, performance status,
GPS: Glascow prognostic score
Table 2 Univariate analysis of clinical factors and GPS for
overall survival (n = 402)
Patients (%) mOS months (95% CI) P-value
Age
<60 203 (50.5) 11.6 (10.1-13.2) 0.808
≥ 60 199 (49.5) 12.0 (9.9-14.1)
Gender
Male 293 (72.9) 11.7 (10.1-13.3) 0.952
Female 109 (27.1) 12.1 (10.6-13.6)
Liver Mets
Yes 125 (31.1) 11.4 (8.5-14.3) 0.352
No 277 (68.9) 12.0 (10.7-13.3)
Peritoneal Mets
Yes 159 (39.6) 9.9 (8.4-11.5) 0.023
No 243 (60.4) 13.0 (11.2-14.8)
Bone Mets
Yes 28 (7.0) 8.2 (7.1-9.3) 0.117
No 374 (93.0) 12.1 (10.9-13.2)
Albumin
<3.5 77 (19.2) 7.7 (5.9-9.5) 0.001
≥ 3.5 325 (80.8) 12.4 (10.7-14.2)
CRP
≤ 1 262 (64.9) 14.8 (12.7-17.0) 0.001
>1 140 (34.8) 8.7 (7.3-10.2)
ECOG PS
0-1 329 (81.8) 12.4 (10.9-13.8) 0.003
≥ 2 73 (48.2) 8.7 (7.3-10.0)
GPS
0 238 (59.2) 15.3 (13.1-17.5) 0.001
1 111 (27.6) 8.9 (7.2-10.7)
2 53 (13.2) 7.6 (4.9-10.2)
mOS: median overall survival, Mets: metastasis, CRP: C-reactive protein, ECOG
PS: Eastern Cooperative Oncology Group, performance status, GPS: Glascow
prognostic score
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Page 3 of 7mg/dL, CRP > 1 mg/dL, PS ≥ 2, GPS ≥ 1 (Table 1). The
univariate analysis also demonstrated that 5 clinical fac-
tors were significantly associated with a shorter OS;
these factors included peritoneal metastasis, albumin <
3.5 mg/dL, CRP >1 mg/dL, PS ≥ 2, and GPS ≥ 1( T a b l e
2).
Cox multivariate analysis for PFS and OS was per-
formed. Among the clinical factors, those with P <0 . 2
were selected and included in the multivariate regres-
sion analysis using the Cox proportional hazards regres-
sion model. The result of the analysis identified the
independent prognostic factors for PFS and OS. The
independent poor prognostic factors for PFS were PS ≥
2 (HR 1.37, 95% CI 1.02-1.84; P = 0.035), CPR >1 mg/
dL (HR 1.64 95% CI 1.28-2.09; P = 0.001), and bone
metastasis (HR 1.74, 95% CI 1.14-2.65; P =0 . 0 0 9 ) .T h e
independent prognostic factors for OS were PS ≥ 2( H R
1.33, 95% CI 1.01-1.76; P = 0.037), GPS 1 (HR 1.75, 95%
CI 1.37-2.26; P = 0.001), GPS 2 (HR 1.79, 95% CI 1.29-
2.47; P = 0.001), and bone metastasis (HR 1.61 95% CI
1.08-2.39; P = 0.017) (Table 5). Figure 1 shows the sur-
vival curve for patients according to GPS.
In this study, GPS 1 was most commonly found to be
a result of an elevated CRP (87 of 111, 78.4%). Among
the patients with GPS 1, the patients with increased
CRP and normal albumin level had a better median
progression survival and median overall survival than
the patients with normal CRP and decreased albumin
level; however, the difference was not statistically signifi-
cant (Table 6).
Discussion
CRP is a nonspecific but sensitive marker of systemic
inflammatory response, and might be expressed in selected
tumor cells [13]. The biological basis for the correlation
between elevations in this general marker of systemic
inflammation and disease risk and outcome are not com-
pletely understood. The liberation of multiple proinflam-
matory cytokines, including interleukin-1 (IL-1), IL-6, and
tumor necrosis factor-a from the tumor environment
eventually results in the induction of CRP synthesis from
the liver and other tissues [14]. Based on many recent stu-
dies, it is now widely accepted that an elevated CRP value
is a reliable indicator of poor prognosis for certain malig-
nant tumors including melanoma, non-Hodgkin’sl y m -
phoma, colorectal, lung, prostate and ovary [12,15,16].
Several studies demonstrated that low albumin con-
centrations are significantly associated with poorer sur-
vival in patients with gastric cancer [17,18]. In patients
with gastric cancer, it is recognized that there may be
reduced caloric intake due to stenosis of the cardia or
pylorus. However, several recent reports showed that
the systemic inflammatory response plays a major role
in the progressive nutritional and functional decline of
patients with cancer [19]. Indeed, measurement of the
systemic inflammatory response, particularly CRP, has
been included in the definition of cancer cachexia,
together with weight loss and reduced calorie intake
[20]. It thus appears that the development of hypoalbu-
minemia is secondary to an ongoing systemic inflamma-
tory response and poor cancer specific survival is
secondary to the systemic inflammatory response in
Table 3 Regimens of chemotherapy
Regimen No. of
patients
%
Taxane/Cisplatin 191 47.5
Taxane/Cisplatin/5-FU 94 23.4
Irinotecan/5-FU 9 2.2
Oxaliplatin/5-FU 52 12.9
5-FU (oral or infusional fluoropyrimidines)/
Cisplatin
21 5.2
Oral fluoropyrimidine 35 8.7
Total 402 100.0
Table 4 Response to chemotherapy (n = 402)
Response No of Patient %
CR 25 6.2
PR 120 29.9
SD 140 34.8
PD 103 25.6
ORR (CR + PR) 145 36.1
DCR (CR + PR + SD) 285 70.9
NE 14 3.5
Total 402 100.0
CR: complete response, PR: partial response, SD: stable disease, PD:
progressive disease, ORR: overall response rate, DCR: disease control rate, NE:
not evaluable
Table 5 Progression free survival and overall survival in
advanced gastric cancer patients receiving first-line
chemotherapy (multivariate analysis)
Factors Progression free survival
Hazard ratio (95% CI) P-value
ECOG PS (≥ 2) 1.37 (1.02-1.84) 0.035
CRP (>1) 1.64 (1.28-2.09) 0.001
Bone metastasis 1.74 (1.14-2.65) 0.009
Overall survival
Hazard ratio (95% CI) P-value
ECOG PS (≥ 2) 1.33 (1.01-1.76) 0.037
GPS (1) 1.75 (1.37-2.26) 0.001
GPS (2) 1.79 (1.29-2.47) 0.001
Bone metastasis 1.61 (1.08-2.39) 0.017
ECOG PS: Eastern Cooperative Oncology Group, performance status, CRP: C-
reactive protein
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both the presence of a systemic inflammatory response
and the progressive nutritional decline of the patient
with advanced cancer. In this study, GPS 1 was most
commonly associated with increased CRP (87 of 111,
78.4%). Our results also demonstrated that increased
CRP was associated with shorter PFS, and a GPS ≥ 1
was associated with shorter OS in advanced gastric can-
cer in palliative chemotherapy settings.
In gastric cancers, almost all studies evaluated the
prognostic value of the preoperative CRP in resettable
tumors [12]. In a recent study of 204 patients who
underwent curative resection of gastric carcinoma, preo-
perative CRP elevations were found to be independently
predictive of shorter overall survival [22]. To our knowl-
edge, only 2 studies demonstrated the relationship
between GPS and cancer specific survival in unresect-
able gastric cancer [4,5]. These studies showed that GPS
was a significant independent predictor of cancer survi-
val in unresectable gastroesophageal cancer. However,
these studies also included esophageal cancer and
diverse treatment modalities such as chemotherapy,
radiotherapy, and endoscopic laser were used for pallia-
tive treatment. In our study, we only enrolled patients
receiving first-line palliative chemotherapy for gastric
adenocarcinoma. We excluded gastroesophageal junc-
tion cancer, because the underlying pathophysiology of
cancers of the gastroesophageal junction and the corre-
sponding therapeutic approach differ substantially from
those for gastric cancer proper [23].
Although gastric cancer is thought to spread more
commonly to the peritoneum or liver than to bone, the
reported incidence of skeletal lesions varies between 1
and 45% [24]. The presence of bone metastasis has
Figure 1 GPS was an independent poor prognostic factor for OS in recurred or metastatic gastric cancer patients receiving first-line
palliative chemotherapy (GPS = 1, HR 1.75 95% CI 1.37-2.26, P = 0.001; GPS = 2, HR 1.79, 95% CI 1.29-2.47, P = 0.001).
Table 6 Patients with increased CRP and normal albumin
level had a better median progression free survival and
median overall survival than patients with normal CRP
and decreased albumin level in the patients with GPS 1
(not statistically significant)
Patients with increased
CRP and normal
albumin level (n =8 7 )
Patients with normal
CRP and decreased
albumin level (n = 24)
P-value
mPFS
(months)
3.433 2.533 0.489
(95% CI 2.648-4.219) (95% CI 0.000-5.284)
mOS
(months)
8.9 8.7 0.915
(95% CI 7.003-10.930) (95% CI 5.779-11.621)
mPFS: median progression free survival, mOS: median overall survival, CRP: C-
reactive protein
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dies of Korean gastric cancer patients. In their report
analyzing 1,455 metastatic gastric cancer patients who
received first-line chemotherapy, Lee et al. reported that
t h ep r e s e n c eo fb o n em e t a s t a s i sw a sa ni n d e p e n d e n t
poor prognostic factor [18]. In our study, bone metasta-
sis was also independently associated with poor prog-
nosis (median OS 8.2 vs. 12.1 months, bone metastasis
(+) vs. (-), P = 0.017).
The mechanism by which a systemic inflammatory
response might influence cancer survival is not clear. It
may be that an elevated systemic inflammatory response
is associated with a poor local immune response to the
tumor and therefore increased lymph node spread and
metastasis [21]. Also, the presence of a systemic inflam-
matory response and the associated nutritional decline
may influences tolerance and compliance with active
treatment [25,26]. Andreyev et al. reported that the
poorer outcome of chemotherapy in advanced gastroin-
testinal cancer patients with weight loss appears to be as
a result of receiving less chemotherapy due to toxicity
rather than poorer tumor response [27]. In this study,
among the patients with GPS 1, the patients with normal
CRP and decreased albumin level (n = 24) had a tendency
to have a poorer median progression free survival and
median overall survival than the patients with increased
CRP and normal albumin level (n = 87). In this group of
the patients, decreased albumin level might be associated
with the chronic nutritional decline and poor ECOG PS.
Conclusions
The presence of a systemic inflammatory response as
evidenced by the CRP and GPS, appears to be a useful
indicator of prognosis in patients receiving first-line che-
motherapy for metastatic gastric cancer. Poor perfor-
mance status and bone metastasis were also associated
with poor prognosis. CRP, GPS, and bone metastasis are
easily identifiable and objective clinical parameters.
These parameters could facilitate the individual patient
risk assessment and thus, a more appropriate prediction
of survival for each patient.
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